COVID-19患者出院后血栓形成风险的相关因素
该队列研究纳入2020年3月1日至11月30日在Henry Ford Health System 5家医院住院的2832例COVID-19成年患者,随访出院后90天,静脉血栓栓塞发生率为1.3%(36例),动脉血栓栓塞为0.5%(15例)。静脉血栓栓塞风险随时间下降(Mann-Kendall趋势检验P<.001),中位发生时间为16天;动脉血栓栓塞风险随时间无变化(P=.37),中位发生时间为37天。有静脉血栓栓塞史(OR 3.24)、峰值D-二聚体>3 μg/mL(OR 3.76)、出院前C反应蛋白>10 mg/dL(OR 3.02)与出院后静脉血栓栓塞风险升高相关;出院时治疗性抗凝处方与静脉血栓栓塞发生率降低相关(OR 0.18,P=.02)。作者认为,不支持对所有未筛选的COVID-19患者延长血栓预防,但对于上述高危且出血风险低的患者,可考虑出院后抗凝。
要点
- 2832例COVID-19住院患者出院后90天内静脉血栓栓塞发生率为1.3%(36例:16例肺栓塞、18例深静脉血栓、2例门静脉血栓)。
- 静脉血栓栓塞风险随时间下降(Mann-Kendall趋势检验P<.001),中位发生时间16(IQR 7-43)天。
- 有静脉血栓栓塞史(OR 3.24;95%CI 1.34-7.86)、峰值D-二聚体>3 μg/mL(OR 3.76;95%CI 1.86-7.57)、出院前C反应蛋白>10 mg/dL(OR 3.02;95%CI 1.45-6.29)与出院后静脉血栓栓塞风险升高相关。
- 出院时治疗性抗凝处方与静脉血栓栓塞发生率降低相关(OR 0.18;95%CI 0.04-0.75;P=.02)。
- 作者认为,不支持对所有未筛选的COVID-19患者延长血栓预防;对上述高危且出血风险低的患者,可考虑出院后抗凝。
适用人群与场景
- 2020年3月1日至11月30日在Henry Ford Health System 5家医院住院、经SARS-CoV-2检测阳性确诊COVID-19的成年患者。
- 出院后90天内随访动脉和静脉血栓栓塞事件。
诊断标准与关键阈值
- 出院后90天内新发症状性动脉和静脉血栓栓塞事件,采用国际疾病统计分类第十版(ICD-10)编码识别。
处置流程与药物剂量
- 出院时治疗性抗凝处方与静脉血栓栓塞发生率降低相关(OR 0.18;95%CI 0.04-0.75;P=.02)。
- 作者认为,对于有静脉血栓栓塞史、峰值D-二聚体>3 μg/mL、出院前C反应蛋白>10 mg/dL的高危患者,若出血风险低,可考虑出院后抗凝。
研究设计与关键结果
- 队列研究,纳入2832例COVID-19住院成年患者,平均(SD)年龄63.4(16.7)岁(IQR 53-75岁),男性1347例(47.6%)。
- 出院后静脉血栓栓塞事件36例(1.3%):16例肺栓塞、18例深静脉血栓、2例门静脉血栓;动脉血栓栓塞事件15例(0.5%):1例短暂性脑缺血发作、14例急性冠脉综合征。
- 静脉血栓栓塞风险随时间下降(Mann-Kendall趋势检验P<.001),中位(IQR)发生时间16(7-43)天;动脉血栓栓塞风险随时间无变化(Mann-Kendall趋势检验P=.37),中位(IQR)发生时间37(10-63)天。
- 有静脉血栓栓塞史(OR 3.24;95%CI 1.34-7.86)、峰值D-二聚体>3 μg/mL(OR 3.76;95%CI 1.86-7.57)、出院前C反应蛋白>10 mg/dL(OR 3.02;95%CI 1.45-6.29)与出院后静脉血栓栓塞风险升高相关。
- 出院时治疗性抗凝处方与静脉血栓栓塞发生率降低相关(OR 0.18;95%CI 0.04-0.75;P=.02)。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,不支持对所有未筛选的COVID-19患者延长血栓预防。
- 作者认为,对于有静脉血栓栓塞史、峰值D-二聚体>3 μg/mL、出院前C反应蛋白>10 mg/dL的高危患者,若出血风险低,可考虑出院后抗凝。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: COVID-19 is associated with a high incidence of thrombotic events; however, the need for extended thromboprophylaxis after hospitalization remains unclear.
OBJECTIVE: To quantify the rate of postdischarge arterial and venous thromboembolism in patients with COVID-19, identify the factors associated with the risk of postdischarge venous thromboembolism, and evaluate the association of postdischarge anticoagulation use with venous thromboembolism incidence.
DESIGN, SETTING, AND PARTICIPANTS: This is a cohort study of adult patients hospitalized with COVID-19 confirmed by a positive SARS-CoV-2 test. Eligible patients were enrolled at 5 hospitals of the Henry Ford Health System from March 1 to November 30, 2020. Data analysis was performed from April to June 2021.
EXPOSURES: Anticoagulant therapy after discharge.
MAIN OUTCOMES AND MEASURES: New onset of symptomatic arterial and venous thromboembolic events within 90 days after discharge from the index admission for COVID-19 infection were identified using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes.
RESULTS: In this cohort study of 2832 adult patients hospitalized with COVID-19, the mean (SD) age was 63.4 (16.7) years (IQR, 53-75 years), and 1347 patients (47.6%) were men. Thirty-six patients (1.3%) had postdischarge venous thromboembolic events (16 pulmonary embolism, 18 deep vein thrombosis, and 2 portal vein thrombosis). Fifteen (0.5%) postdischarge arterial thromboembolic events were observed (1 transient ischemic attack and 14 acute coronary syndrome). The risk of venous thromboembolism decreased with time (Mann-Kendall trend test, P < .001), with a median (IQR) time to event of 16 (7-43) days. There was no change in the risk of arterial thromboembolism with time (Mann-Kendall trend test, P = .37), with a median (IQR) time to event of 37 (10-63) days. Patients with a history of venous thromboembolism (odds ratio [OR], 3.24; 95% CI, 1.34-7.86), peak dimerized plasmin fragment D (D-dimer) level greater than 3 μg/mL (OR, 3.76; 95% CI, 1.86-7.57), and predischarge C-reactive protein level greater than 10 mg/dL (OR, 3.02; 95% CI, 1.45-6.29) were more likely to experience venous thromboembolism after discharge. Prescriptions for therapeutic anticoagulation at discharge were associated with reduced incidence of venous thromboembolism (OR, 0.18; 95% CI, 0.04-0.75; P = .02).
CONCLUSIONS AND RELEVANCE: Although extended thromboprophylaxis in unselected patients with COVID-19 is not supported, these findings suggest that postdischarge anticoagulation may be considered for high-risk patients who have a history of venous thromboembolism, peak D-dimer level greater than 3 μg/mL, and predischarge C-reactive protein level greater than 10 mg/dL, if their bleeding risk is low.
参考来源
- Li P, Zhao W, Kaatz S, et al. Factors Associated With Risk of Postdischarge Thrombosis in Patients With COVID-19. JAMA Netw Open. 2021. PMID: 34807256. doi:10.1001/jamanetworkopen.2021.35397
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。